Sanofi to Showcase Innovative Solutions at Its Sixth CIIE Appearance, Continuing Its 'Miracle' Journey

ShanghaiOctober 16, 2023PR Newswire -- The 6th China International Import Expo (hereinafter referred to as "CIIE") is set to open in Shanghai this November. As a "five-year friend" of previous CIIEs, Sanofi, a world-leading innovative pharmaceuticals and healthcare company, will participate for the sixth consecutive year. From November 5th to 10th, Sanofi will unveil its "Miracle Lab" booth at the National Exhibition and Convention Center, showcasing the company’s cutting-edge pipeline and first-in-class innovations through diverse formats. Under the theme of "Chasing Scientific Miracles," Sanofi demonstrates its steadfast commitment to patients and society in China.

Wang Shi, President of Sanofi Greater ChinaIndicates:"In China40For many years, Sanofi has been fortunate to seize the new opportunities of China's shared openness with the world; we have been walking alongside the CIIE for six years, and we thank it for creating a fantastic platform for multinational companies like Sanofi to showcase innovative achievements, deepen exchanges, and enhance cooperation. On this fertile ground of openness and innovation in China, the vast prospects and boundless opportunities further strengthen our confidence and determination to deepen our roots in China, and we will continue to commit ourselves to...‘Pursuing Scientific Miracles', relying on and contributing to the group's rich R&D pipeline, accelerate the introduction of more high-quality innovative products and solutions for Chinese patients, becoming a driving force to help achieve‘Healthy China2030'A reliable partner, bringing more vitality to life."

This year, Sanofi's booth will deepen the theme of "Pursuing Scientific Miracles, Revitalizing the Radiance of Life" and appear at the CIIE in the form of a "Miracle Lab," using technologies such as holographic projection to bring an ultimate immersive experience to the audience.

This time, Sanofi will showcase the latest advancements in its rich and diverse R&D pipeline (approximately 80 clinical R&D projects as of July 2023) and will highlight several transformative innovations in the field of immunology, such as Dupixent, a star product for atopic dermatitis driven by type 2 inflammation.^®(Dupilumab Injection) will showcase the latest advancements in indications; Beyfortus, the world's first long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV) for all infant populations.^®, the world's first and only innovative therapy to delay the onset of Type 1 diabetes, Tzield^TMwill also make a brilliant appearance; in addition, it will bring an innovative therapy for rare diseases: a new generation enzyme replacement therapy (ERT) drug for the treatment of Pompe disease, Nyalzane.^®。

As a "full-time participant" that has actively participated in the CIIE for six consecutive years, Sanofi continues to benefit from the "spillover effects" of the CIIE. Thanks to the CIIE platform, Sanofi has witnessed the "China speed" at which exhibits are rapidly transformed into commercial products — exemplified by its star product Dupixent.^®(Taking dupilumab injection as an example, after its debut at the first China International Import Expo in 2018, every step from approval, market launch to medical insurance implementation has demonstrated the "China speed" of accelerating the accessibility of innovative drugs. It has also become a vivid example of China's efforts to expedite the introduction of breakthrough innovative medicines to meet urgent clinical needs.)

The CIIE is a globally acclaimed window of openness, not only opening the door of opportunity for multinational enterprises but also creating precious opportunities for exchanges with industry partners. As its layout and investment in China continue to expand and deepen, Sanofi will remain committed to leveraging the CIIE to achieve mutual benefits and win-win outcomes with all parties. It will actively participate in building China's innovative pharmaceuticals ecosystem and become a reliable partner in realizing "Healthy China 2030," revitalizing the vitality of life for the vast number of Chinese people.

Sanofi Forward-Looking Statements

This press release contains1995Forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact. These statements include forecasts and estimates of the marketing and other potential of products, or forecasts and estimates of potential future revenues from products. Such statements often use words like"Expectation"、"Expected"、"Believe"、"Plan"、"Estimate"、"Plan"Terms such as "believes," "anticipates," "expects," and similar expressions are used to identify forward-looking statements. Although the management of Sanofi believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements and information are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, which could cause actual results and developments to differ materially from those expressed, implied, or predicted in the forward-looking statements. These risks and uncertainties include, but are not limited to, decisions or delays by regulatory authorities, or decisions by other entities regarding matters that may affect the availability or commercial potential of product candidates; the possibility that approved products may not achieve commercial success; inherent uncertainties in research and development; future clinical data and analyses, including data and analyses collected post-marketing; unexpected safety, quality, or manufacturing issues; general competition; risks related to future litigation over intellectual property and the ultimate outcome of such litigation; and fluctuating economic and market conditions, including the impact of the COVID-19 pandemic on us, our customers, suppliers, and other business partners, as well as the financial condition of any of these parties, including its impact on our employees and the global economy. Significant impacts of the COVID-19 pandemic on any of these parties could also negatively affect us. This situation is rapidly evolving and may lead to additional impacts that we are currently unaware of, potentially exacerbating previously identified risks. These risks and uncertainties also include those detailed in Sanofi's public filings with the U.S. Securities and Exchange Commission (SEC).SEC) and the French Financial Markets Authority (AMF) has been discussed or clarified in the report, including those listed in Table20-FSanofi Annual Report (as of2022Year12Month31Day) in"Risk Factors"And"Forward-Looking StatementsWarning"Unless there are applicable legal requirements, Sanofi assumes no obligation to update or modify any forward-looking information and statements.